Traditionally, exercise interventions for cancer patients have required in-person attendance at rehabilitation centers or fitness facilities, presenting logistical challenges such as transportation barriers, scheduling conflicts, and treatment-related fatigue. DEFEND proposes a paradigm shift by harnessing remote technologies to deliver exercise programs. Specifically, participants will engage in twice-weekly supervised exercise sessions conducted via video calls, led by oncology-trained exercise coaches experienced in tailoring interventions to the unique physiological and psychosocial needs of cancer patients. This model not only facilitates accessibility and adherence but also maintains professional oversight critical to safety and efficacy.

Eligible participants, between the ages of 18 and 65, are currently receiving chemotherapy with curative intent. After enrollment, each will be equipped with resistance bands and a stationary bicycle, enabling a diverse range of strength and aerobic training exercises vital for maintaining muscular function and cardiovascular health. In addition, continuous activity monitoring will be employed using wearable devices such as Fitbit trackers, allowing objective quantification of physical activity levels throughout the intervention. This hybrid monitoring strategy integrates subjective and objective metrics, enhancing the granularity of data collected for rigorous analysis.

The DEFEND trial’s primary objective is to determine the feasibility of implementing a remote exercise intervention in a representative cohort of cancer patients. This encompasses evaluating recruitment capabilities, adherence rates, and retention, with a particular focus on inclusivity across diverse populations, including individuals from rural areas and underserved communities often excluded from conventional trials due to geographical or socioeconomic constraints. By addressing these disparities, the study aspires to create scalable models that could be broadly adopted in clinical oncology settings.

Secondary exploratory outcomes will assess changes in physical function, utilizing validated measures such as grip strength dynamometry and the 6-Minute Walk Test to quantify exercise-related improvements objectively. Furthermore, patient-reported outcomes capturing fatigue levels, quality of life, and employment status over time will be analyzed to elucidate the broader psychosocial impact of sustained exercise during chemotherapy. These multidimensional assessments are crucial given that cancer-associated fatigue is one of the most pervasive and disruptive symptoms adversely affecting patient well-being and functionality.

Crucially, DEFEND builds upon an expanding corpus of literature demonstrating exercise’s salutary effects in oncology, including reductions in treatment-related adverse effects and enhanced survival. Yet, despite robust evidence supporting exercise as a non-pharmacological adjunct therapy, implementation barriers have hindered its integration into routine care. The emergence of telehealth, accelerated by recent healthcare transformations, presents an unprecedented opportunity to surmount these barriers, making exercise interventions more accessible, personalized, and adaptable.

The trial’s design integrates oncology expertise with exercise science, deploying oncology-trained exercise coaches to deliver individualized guidance. These professionals will leverage telecommunication tools to safely modulate exercise intensity and address patient concerns in real time, ensuring that the program responds dynamically to fluctuations in treatment tolerance and side-effect profiles. This real-time interaction, combined with remote monitoring of adherence and physiological responses, exemplifies the forward-thinking integration of technology and clinical care.

By circumventing common logistical challenges such as transportation difficulties and fatigue-induced motivation losses, the DEFEND trial’s at-home exercise model aspires to achieve higher adherence and durability of physical activity behaviors. The anticipated maximum duration of the intervention is six months, coinciding with the chemotherapy treatment timeline, with assessments at baseline, chemotherapy completion, and three months post-treatment to evaluate both immediate and sustained effects.

If successful, the DEFEND trial could herald a transformative shift in oncology supportive care, establishing telehealth-delivered exercise programs as integral components of comprehensive cancer treatment protocols. Given the expanding embrace of telemedicine across healthcare disciplines, this model could serve as a blueprint for scalable interventions that enhance patient outcomes while mitigating the burden on healthcare infrastructure.

The trial is slated to commence participant enrollment in late 2025, with data collection culminating in early 2027. It is supported by the National Institutes of Health and the National Cancer Institute, underscoring the significance attributed to innovative supportive care strategies that promote physical function, reduce fatigue, and prevent disability—key determinants of cancer survivorship and quality of life.

In summary, the Alliance’s DEFEND trial embodies a confluence of technological innovation, clinical expertise, and patient-centered care, aiming to redefine the landscape of exercise oncology. By enabling virtual access to supervised training customized to the unique challenges faced by cancer patients during chemotherapy, DEFEND could demonstrate that fidelity to exercise interventions and meaningful clinical outcomes are attainable beyond traditional rehabilitation paradigms. This endeavor exemplifies a forward-thinking approach to harnessing telehealth for durable improvements in cancer care.

Subject of Research: People
Article Title: —
News Publication Date: —
Web References: https://www.clinicaltrials.gov/study/NCT07059884
References: Alliance A222302 / NCT07059884 – Distance-based exercise to preserve function and prevent disability (DEFEND)
Image Credits: Dana-Farber Cancer Institute
Keywords: Oncology, Cancer, Breast cancer, Blood cancer, Bone cancer, Brain cancer, Physical exercise, Public health, Clinical trials, Chemotherapy, Radiation therapy, Physical rehabilitation, Physical therapy, Personalized medicine, Wearable devices

Melding innovative biomaterials with cellular therapies, this research builds on the intrinsic properties of mesenchymal stem cells, which are well known for their ability to differentiate into various cell types and secrete a multitude of growth factors. These factors are crucial for tissue repair and the reduction of inflammation. The integration of PMSCs into a biocompatible hydrogel matrix allows for targeted delivery and sustained release of these therapeutic agents directly at the site of damage, facilitating a more effective healing process.

The methodology of this clinical trial is particularly noteworthy. A carefully curated sample of participants was subjected to the rigorous standards of a randomized controlled trial. With patients receiving either the PMSC-embedded hydrogel or a placebo, the research team meticulously tracked healing progress using various clinical assessments and biomarkers. This dual-approach not only underscores the commitment to scientific rigor but also ensures that the findings would be robust and applicable to a broader patient population.

As part of the trial, participants were monitored over several weeks, with assessments occurring at predetermined intervals. The data collection focused on a variety of parameters, including the rate of epithelialization, the degree of inflammation, and patient-reported outcomes regarding pain and quality of life. Not only did researchers prioritize objective clinical measures, but they also sought to gauge the subjective experiences of participants, thereby enriching the data with holistic insights.

One of the most compelling findings from the study was the demonstrable speed of recovery in patients receiving the PMSC hydrogel treatment compared to those on placebo. Participants treated with the experimental hydrogel exhibited significant improvements in skin integrity and comfort levels, suggesting that the stem cell therapy may not only expedite healing but also alleviate some of the pain and discomfort associated with traditional recovery methods.

The clinical trial’s results have garnered attention from the scientific community, as they collectively suggest that the PMSC-embedded hydrogel could redefine the landscape of post-radiation care. By focusing on local application rather than systemic treatment, this innovative approach minimizes potential side effects often related to broader therapeutic interventions, thus presenting a safer alternative for vulnerable patients.

The implications of this research extend beyond mere treatment efficacy. By illustrating the potential of placental mesenchymal stem cells, the study opens avenues for further exploration into their applications across various medical fields, including dermatology and plastic surgery. The regenerative capabilities of these stem cells, demonstrated in their use to repair radiation-induced skin injuries, could potentially be adapted to treat other dermatological conditions, or even enhance the outcomes of surgical procedures.

Moreover, the findings may catalyze further research into optimizing the hydrogel formulation. The study’s authors indicated a keen interest in enhancing the gel’s properties to improve cell retention and extend the lifespan of the released growth factors. Such advancements would ultimately bolster the gel’s effectiveness, making it a pivotal tool not just for skin damage but potentially for a range of other muscular or tissue injuries that warrant expedited healing.

The commitment to advancing science in this space has also spurred an exploration of different types of stem cells, beyond those derived from the placenta. Investigating other sources like adipose tissue or bone marrow could further enrich the understanding of how various stem cell types interact with diverse biomaterials. Such explorations could lead to customizable treatments tailored to individual patient needs, resonating with the movement towards personalized medicine.

Interestingly, the study highlights not only the promise of this treatment but also the ethical considerations of using placental tissue. Experts have begun to discuss the ethical procurement of such materials, ensuring that their use respects donor rights while harnessing the potential benefits that placental-derived products can offer. These considerations serve as a reminder that as science progresses, it must do so responsibly, ever mindful of the implications and responsibilities toward both patients and sources.

With the positive outcomes of this double-blind trial, it is likely that regulatory bodies will take swift notice of these findings. The path towards potential FDA approval could begin, presenting a transformative moment for patients who have long suffered from the side effects of radiation therapy. If further studies confirm these initial results, we may soon see the PMSC hydrogel approach accepted as part of clinical practice, altering how skin damage related to radiation is managed in healthcare settings.

As excitement builds around these findings, it serves as a testament to the power of innovation and collaboration in the field of regenerative medicine. The intersection of technology, biology, and material science has yielded significant progress in understanding how we can leverage the body’s innate healing mechanisms to address complex medical issues. The journey from research to application may be challenging, but the potential benefits are vast, igniting hope in patients and advocates alike.

In conclusion, the double-blind randomized phase II clinical trial underscores the promising potential of a placental mesenchymal stem cell-embedded hydrogel in treating radiation-induced skin damage. This remarkable research not only enhances our understanding of cell therapy in clinical settings but also opens the door to future innovations that could improve patient outcomes across various therapeutic arenas. As the scientific community eagerly anticipates the next steps in this research, it is clear that the integration of stem cell biology and biomaterial science holds immense promise for shaping the future of regenerative medicine.

Subject of Research: Application of placental mesenchymal stem cell-embedded biomaterial hydrogel in repairing radiation-induced skin damage.

Article Title: Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial.

Article References:

Tian, L., Han, Z., Jiang, M. et al. Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial.
J Transl Med 23, 1057 (2025). https://doi.org/10.1186/s12967-025-07060-7

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07060-7

Keywords: placental mesenchymal stem cells, hydrogel, radiation-induced skin damage, regenerative medicine, clinical trial.